Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05885464 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: estimated 102 to confirmed 5v12
  2. Primary and study completion dates: Dec 2031 to Dec 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 10 of 10 sites
    v11
  3. Study sites: 8 to 10v10
  4. Study sites: 7 to 8v9
  5. Study sites: 6 to 7v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 4 to 6v7
  2. Study sites: 2 to 4v6
  3. Study sites: 1 to 2v5
  4. 2 versions Re-verified since Jul 25, 2023, no change to tracked fieldsv3-v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.
Trial Details
NCT Number NCT05885464
Lead Sponsor Beam Therapeutics Inc.
Conditions
(from sponsor)		 Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
Related terms Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov